Elite in Pompe Disease

Dr. Mazen M. Dimachkie

Neurology
Kansas University Physicians Inc
3599 Rainbow Blvd, 
Kansas City, KS 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Elite in Pompe Disease
Kansas University Physicians Inc
3599 Rainbow Blvd, 
Kansas City, KS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Mazen Dimachkie, MD is a Clinical Neurophysiologist in Kansas City, KS and has over 34 years of experience in the medical field. He graduated from American University of Beirut / Faculty of Medicine in 1988. He is affiliated with medical facilities LMH Health and University Of Kansas Hospital.

Dr. Dimachkie is rated as an Elite provider by MediFind in the treatment of Pompe Disease. His top areas of expertise are Myositis, Inclusion Body Myositis, Myasthenia Gravis, Pompe Disease, and Thymectomy.

His clinical research consists of co-authoring 182 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 14 articles in the study of Pompe Disease.

Residency
University of Texas Health Science Center
Specialties
Neurology
Licenses
Psychiatry & Neurology in KS
Board Certifications
American Board Of Psychiatry And Neurology Neurology
American Board Of Psychiatry And Neurology Clinical Neurophysiology
American Board Of Psychiatry And Neurology Neuromuscular Medicine
Hospital Affiliations
LMH Health
Languages Spoken
English
Arabic
French
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

KANSAS UNIVERSITY PHYSICIANS INC
3599 Rainbow Blvd, Kansas City, KS 66103
Other Locations
KANSAS UNIVERSITY PHYSICIANS INC
4000 Cambridge St, Suite G600, Kansas City, KS 66160
KANSAS UNIVERSITY PHYSICIANS INC
3901 Rainbow Blvd, Kansas City, KS 66160

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis
Enrollment Status: Recruiting
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drug: MN-166
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects With GNE Myopathy
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects With GNE Myopathy
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drug: N-Acetylmannosamine
Study Phase: Phase 2
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Participants With Painful Diabetic Peripheral Neuropathy
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Participants With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: February 26, 2025
Intervention Type: Other, Biological
Study Phase: Phase 3
Long-term, Prospective, Non-interventional, Extension of a Phase III, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety & Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy
Long-term, Prospective, Non-interventional, Extension of a Phase III, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety & Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: February 25, 2025
Intervention Type: Drug, Genetic
Study Phase: Phase 3
International GBS Outcome Study (IGOS): a Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS).
International GBS Outcome Study (IGOS): a Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS).
Enrollment Status: Completed
Publish Date: December 12, 2024
Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells
Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Device
Study Phase: Not Applicable
Influence of NT5c1A Antibodies on Disease Progression, Clinical Phenotype and Blood and Muscle Biomarkers in Sporadic Inclusion Body Myositis - A Prospective Evaluation (INSPIRE-IBM Study)
Influence of NT5c1A Antibodies on Disease Progression, Clinical Phenotype and Blood and Muscle Biomarkers in Sporadic Inclusion Body Myositis - A Prospective Evaluation (INSPIRE-IBM Study)
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2024
Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)
Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Other, Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Drug
Study Drug: Lenabasum
Study Phase: Phase 3
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Enrollment Status: Completed
Publish Date: October 30, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
Enrollment Status: Completed
Publish Date: March 30, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Enrollment Status: Completed
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

182 Total Publications

Consensus nomenclature and abbreviation for anti-synthetase syndrome: an IMACS project.
Consensus nomenclature and abbreviation for anti-synthetase syndrome: an IMACS project.
Journal: Rheumatology (Oxford, England)
Published: March 04, 2025
Similar Doctors
Experienced in Pompe Disease
Dr. Jeffrey M. Statland
Neurology
Experienced in Pompe Disease
Dr. Jeffrey M. Statland
Neurology

Kansas University Physicians Inc

4000 Cambridge St, Suite G600, 
Kansas City, KS 
 (0.4 mi)
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Statland is a Neurologist in Kansas City, Kansas. Dr. Statland and is rated as an Elite provider by MediFind in the treatment of Pompe Disease. His top areas of expertise are Facioscapulohumeral Muscular Dystrophy (FSHD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Paramyotonia Congenita, and Gastrostomy. Dr. Statland is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dimachkie's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 10 Distinguished Conditions
View All 26 Advanced Conditions
View All 46 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile